How and when I do allogeneic transplant in CLL.

Blood
John Gribben

Abstract

Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and the only approach offered with curative intent in this disease. The availability novel agents, including the B-cell receptor inhibitors ibrutinib, acalabrutinib, and idelalisib, as well as venetoclax, which targets the BCL2 pathway, and the success of these agents in treating high-risk disease patients have made it more difficult to assess who should be considered for allo-SCT and when in the treatment course. In this review, I will discuss the different treatment options available for the treatment of high-risk CLL and how allo-SCT fits into the treatment algorithm in the era of novel agents.

References

Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carol MorenoEmili Montserrat
Jun 21, 2005·The Journal of Clinical Investigation·Güllü GörgünJohn G Gribben
Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Aug 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johannes ScheteligPeter Dreger
Oct 24, 2009·Blood·John G Gribben
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Mar 8, 2012·Blood·Thorsten ZenzStephan Stilgenbauer
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Jan 15, 2014·Blood·Sameer A ParikhTait D Shanafelt
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Oct 11, 2014·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Oct 18, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohamed A Kharfan-DabajaBipin N Savani

❮ Previous
Next ❯

Citations

Aug 4, 2018·Blood·John G Gribben
Dec 7, 2018·Hematology·Jennifer R Brown
May 17, 2019·Leukemia & Lymphoma·Hind RafeiElias J Jabbour
Nov 26, 2019·The Cancer Journal·Joanna M Rhodes, Stephen J Schuster
Dec 7, 2019·Hematology·Barbara EichhorstMichael Hallek
Sep 18, 2020·Science Translational Medicine·Pavan BachireddyCatherine J Wu
Aug 3, 2019·Journal for Immunotherapy of Cancer·Richard Lemal, Olivier Tournilhac
Mar 31, 2019·Targeted Oncology·Fabienne Lucas, Jennifer A Woyach
Nov 16, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Suman PaulDouglas E Gladstone
Jun 9, 2021·Hematology/oncology Clinics of North America·Othman Al-SawafKirsten Fischer
Jul 3, 2021·International Journal of Molecular Sciences·Paolo SportolettiEmanuela Rosati
Dec 7, 2021·Journal of the Egyptian National Cancer Institute·M M KhalifaA R Mansour

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.